Tempest Therapeutics (NASDAQ:TPST) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Tempest Therapeutics (NASDAQ:TPST) to a hold rating in a research note issued to investors on Saturday.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempest Therapeutics in a research note on Monday, December 29th. Zacks Research raised Tempest Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

Tempest Therapeutics Price Performance

NASDAQ TPST opened at $1.96 on Friday. The business has a 50 day simple moving average of $2.11 and a 200 day simple moving average of $4.46. Tempest Therapeutics has a one year low of $1.50 and a one year high of $12.23. The stock has a market capitalization of $28.11 million, a P/E ratio of -0.30 and a beta of -2.00.

Tempest Therapeutics (NASDAQ:TPST) last released its earnings results on Monday, March 30th. The company reported ($0.62) EPS for the quarter, hitting the consensus estimate of ($0.62). Equities analysts expect that Tempest Therapeutics will post -1.39 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Matthew Angel acquired 231,482 shares of Tempest Therapeutics stock in a transaction on Tuesday, March 24th. The stock was purchased at an average price of $2.16 per share, with a total value of $500,001.12. Following the completion of the purchase, the chief executive officer owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.28% of the company’s stock.

Institutional Investors Weigh In On Tempest Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP acquired a new stake in Tempest Therapeutics in the fourth quarter valued at approximately $33,000. Sabby Management LLC bought a new position in shares of Tempest Therapeutics in the fourth quarter valued at approximately $513,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Tempest Therapeutics by 20.8% in the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after purchasing an additional 27,952 shares in the last quarter. Institutional investors and hedge funds own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.